Therapeutics / Drugs / Clinical / Drug / Research / National blog main / National top stories / New York blog main / New York top stories / San Diego blog main / San Diego top stories / San Francisco / San Francisco blog main / San Francisco top stories / Alexandria Venture Investments / Altitude Life Science Ventures / Autism / balovaptan / Bill Martin / Biomatics Capital / BlackThorn Therapeutics / deals / Depression / Eli Lilly / GV / Johnson & Johnson / Johnson & Johnson Innovation / Life Sciences / Mercury Fund / Neurobehavioral disorders / Polaris Partners / Premier Partners / Roche / Scripps Research Institute / startups / VC / Vertex Ventures HC

Can AI Tools, $76M Lead BlackThorn to Targeted Pysch Drugs?

Posted on: Jun 13, 2019   |   Posted by: Biotech Mag Top

Can AI Tools, $76M Lead BlackThorn to Targeted Pysch Drugs?

It's notoriously tough for experimental psychiatric drugs to succeed in clinical tests. BlackThorn Therapeutics wants to show that an AI-driven, precision approach can make it...

Continue reading ...



Other Posts from Biotech Mag Top